Medical therapy or placebo: rates of progression to glaucoma similar
April 15th 2005Dorado Beach, Puerto Rico—Recently reported results from the European Glaucoma Prevention Study (EGPS) have taken the ophthalmology community by surprise, reported Richard K. Parrish II, MD, at the Current Concepts in Ophthalmology meeting.
Initial results good for wavefront-guided Epi-Lift treatments, more work needed
April 15th 2005Washington, DC — Early results of a study evaluating wavefront-guided customized treatment using the Epi-Lift technique indicate that the Gebauer EpiTome (VisiJet/Advanced Refractive Technologies) works well to separate the corneal epithelium. However, there has been significant interpatient variability so far in the level of postoperative comfort, speed of visual recovery, and time to removal of the therapeutic soft contact lens, reported Terrence P. O'Brien, MD, at the American Society of Cataract and Refractive Surgery meeting.
ASCRS meeting launches at National Air and Space Museum
April 15th 2005Delegates of the American Society of Cataract and Refractive Surgery (ASCRS) and the American Society of Ophthalmic Administrators (ASOA) meeting received a special treat during Friday evening's welcome reception. The attraction: the Smithsonian Institution's National Air and Space Museum.
Acute orbital, periorbital pain may signal arterial dissection
April 15th 2005Atlanta—Arterial dissection can be overlooked in a patient who presents to an ophthalmologist with acute orbital or periorbital pain. Val?rie Biousse, MD, described the appropriate steps to take to ensure an accurate diagnosis and avoid a subsequent cerebral insult.
Silicone hydrogel contact lenses likely accociated with fewer complications
April 15th 2005New Orleans—Silicone hydrogel contact lenses may produce fewer complications for patients because of their high oxygen permeability, although their extended wearability could negate that advantage, suggested Peter R. Kastl, MD, PhD, professor of ophthalmology and adjunct professor of biochemistry, Tulane University, New Orleans.
One doctor's mission is to fulfill a vision
April 15th 2005Patients don't have to live in Los Angeles, New York, or even Seattle to receive top-notch ophthalmic care. In a bucolic college town located in central Washington State, John Boys Smith, MD, offers patients cutting-edge eye care with state-of-the-art medical technology.
Welcome to Ophthalmology Times E-News coverage from ASCRS
April 8th 2005Welcome to Ophthalmology Times E-news, providing daily coverage of the 2005 ASCRS meeting from Washington, D.C., April 16-19.Over the next several days, you will receive "instant" meeting coverage of the top clinical presentations, breaking industry news, the latest new products, and other ophthalmic information. The editors of Ophthalmology Times will cover the ASCRS meeting, gathering the latest news and information, and deliver it daily to your inbox.If you would like to receive these updates in your in-box click www.ophthalmologytimes.com/enews
2005 brings fifth World Cornea Congress
April 1st 2005The Cornea Society is hosting its fifth World Congress preceding the joint meeting of The American Society of Cataract and Refractive Surgery (ASCRS) and the American Society of Ophthalmic Administrators (ASOA). The Congress is held only once every 10 years and will take place on Thursday, April 14, and Friday, April 15, at the Washington Convention Center.
Acuity improves with TTT, study says
April 1st 2005Mountain View, CA—Patients with wet age-related macular degeneration (AMD) who were treated with a transpupillary thermotherapy (TTT) laser protocol showed a significant clinical benefit of improved vision versus those in a sham-treated control group, according to Iridex Corp.
OccuLogix to proceed with RHEO therapy trials
April 1st 2005Toronto—The FDA is allowing OccuLogix Inc. to initiate studies of its RHEO blood filtration system to treat dry age-related macular degeneration after reviewing the Long-term Efficacy in AMD from Rheopheresis in North America (LEARN) protocols.
Positive results reported for AMD treatment
April 1st 2005Plymouth Meeting, PA—Six patients treated with 40 mg of Genaera Corp.'s squalamine lactate (Evizon) had preserved or improved vision in both eyes suffering from wet age-related macular degeneration through a 4-month study, according to the company, which released preliminary results of a phase II clinical trial.
Miravant starts phase III restaporfin trials
April 1st 2005Santa Barbara, CA—Miravant Medical Technologies will conduct phase III clinical trials for rostaporfin (PHOTREX) at 50 investigational sites in central and eastern Europe and the United Kingdom to evaluate a range of patients with wet age-related macular degeneration.
Iris registration system adjusts treatment for ocular rotation
April 1st 2005With the push of a button, refractive surgeons now have the capability to align wavefront-guided customized ablations to the correct corneal site. Iris Registration (IR) technology from VISX for use with CustomVue treatment is the first and only FDA-approved, fully automated, non-contact method available to CustomVue surgeons in the United States. The technology is being regarded for its potential to enhance the further efficacy and safety of custom ablations with the VISX system.